Key facts
- Citizens reiterates its stock rating for Rapport Therapeutics.
- The rating follows the release of competitor trial data.
- The analysis considers the impact of new data on Rapport Therapeutics' market position.
Citizens has maintained its existing stock rating for Rapport Therapeutics. This decision comes in the wake of new clinical trial data from a competitor, which analysts at Citizens have evaluated for its potential implications on Rapport Therapeutics' competitive standing and outlook in the market.
